Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodoxamic Acid SCHEMBL377402 | 1.00 | TSHR (0.74) | TSHRMAPK1LMNACYP1A2CYP3A4 | |
| SCHEMBL12142383 | 1.00 | TSHR (0.74) | TSHRMAPK1LMNACYP1A2CYP3A4 | |
| Iotranic Acid SCHEMBL2109613 | 1.00 | TSHR (0.74) | TSHRMAPK1LMNACYP1A2CYP3A4 | |
| Iotroxic Acid SCHEMBL27729545 | 0.89 | TSHR (0.65) | TSHRMAPK1LMNANPC1RAB9A | |
| Iotetric Acid SCHEMBL37863 | 0.89 | TSHR (0.65) | TSHRMAPK1LMNANPC1RAB9A | |
| Iotroxic Acid SCHEMBL38038 | 0.89 | TSHR (0.65) | TSHRMAPK1LMNANPC1RAB9A | |
| Iotetric Acid SCHEMBL27748028 | 0.89 | TSHR (0.65) | TSHRMAPK1LMNANPC1RAB9A | |
| Iodipamide SCHEMBL29606858 | 0.85 | TSHR (1.00) | TSHRMAPK1CYP3A4MEN1KMT2A | |
| Iodipamide SCHEMBL37678 | 0.85 | TSHR (1.00) | TSHRMAPK1CYP3A4MEN1KMT2A | |
| SCHEMBL12143826 | 0.84 | TSHR (0.80) | TSHRMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115505652-A | Fur dyeing method | 北京广楹汇信息咨询服务中心 | 2022-12-23 | — | — | CN | claimed |
| EP-4710766-A1 | MIXTURES OF AMBRUTICIN WITH AT LEAST ONE FURTHER PESTICIDE | BASF SE (DE) | 2026-03-18 | — | — | EP | disclosed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| EP-4486812-B1 | POLYESTER-POLYURETHANE-POLY(METH)ACRYLIC HYBRID DISPERSION | BASF COATINGS GMBH (DE) | 2026-02-18 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250339367-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| WO-2025223904-A1 | MIXTURES OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS WITH AT LEAST ONE FURTHER PESTICIDE I | BASF SE (DE) | 2025-10-30 | — | — | WO | disclosed |
| EP-4640052-A1 | MIXTURES OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS WITH AT LEAST ONE FURTHER PESTICIDE I | BASF SE (DE) | 2025-10-29 | — | — | EP | disclosed |
| EP-4638436-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250255780-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-08-14 | — | — | US | disclosed |
| EP-4058029-A1 | MULTIMODAL COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| WO-2022192476-A1 | DOSAGE FORMS HAVING EQUIVALENT BIOCOMPARABLE PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022187556-A1 | THERAPEUTIC METHODS AND COMPOSITIONS COMPRISING MAGNETIZABLE NANOPARTICLES | VRG STEM CELL SERVICES INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| EP-4051235-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| US-20220233471-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | US | disclosed |
| CN-112351998-B | PD-L1 binding polypeptides and uses thereof | 苏州智核生物医药科技有限公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-114207523-A | Colored curable resin composition | 住友化学株式会社 | 2022-03-18 | — | — | CN | disclosed |
| CN-107918247-B | Colored curable resin composition | 住友化学株式会社 | 2022-03-18 | — | — | CN | disclosed |
| US-20220061324-A1 | PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | SYNGENTA CROP PROTECTION AG (CH) | 2022-03-03 | — | — | US | disclosed |
| CN-107918246-B | Colored curable resin composition | 住友化学株式会社 | 2022-02-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220233471-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | CYP2C19, PAICS, CYP2B6 | TSHR 2877/4885MAPK1 4820/4885LMNA 1594/4885 |
| US-20220061324-A1 | PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | DDT, ACHE, AADAC | TSHR 3631/4885MAPK1 2805/4885LMNA 4474/4885 |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | TSHR 2501/4885MAPK1 3836/4885LMNA 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.